JOURNAL OF CLINICAL SURGERY ›› 2026, Vol. 34 ›› Issue (8): 851-855.doi: 10.3969/j.issn.1005-6483.20260670

Previous Articles     Next Articles

Progress in perioperative treatment of thymic carcinoma

  

  1. Department of Thoracic Surgery,the First Affiliated Hospital of Sun Yat sen University,Guangzhou 510080,China
  • Received:2026-07-19 Accepted:2026-07-19 Online:2026-08-20 Published:2026-08-20

Abstract: Thymic carcinoma is a rare and aggressive thymic epithelial tumor with high metastatic potential and poor prognosis.Due to its low incidence,relevant clinical studies are relatively limited,and perioperative treatment strategies remain controversial.In recent years,with the promotion of multidisciplinary diagnosis and treatment models and the emergence of novel therapeutic approaches,significant progress has been made in the perioperative management of thymic carcinoma.Based on the latest NCCN guidelines and relevant clinical research evidence,this article systematically reviews the latest advances in perioperative treatment of thymic carcinoma,including preoperative assessment,surgical treatment,neoadjuvant therapy,postoperative adjuvant therapy,and multidisciplinary management.

Key words: thymic carcinoma, perioperative treatment, neoadjuvant therapy, adjuvant radiotherapy, multidisciplinary diagnosis and treatment

[1] ZHANG Yunpeng, WU Heshui, YIN Tao. Precision treatment of pancreatic cancer: from resectability to benefit [J]. JOURNAL OF CLINICAL SURGERY, 2026, 34(7): 721-724.
[2] GUO Shiwei. Precision therapy for pancreatic cancer: current status and future directions: from A to AI [J]. JOURNAL OF CLINICAL SURGERY, 2026, 34(7): 746-751.
[3] ZHANG Zaizhong,ZHAO Pan,XIAO Chunhong,WANG Meiping,HONG Weixuan,FANG Junwei,WANG Lie. Surgical treatment of primary giant gastrointestinal stromal tumor [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(6): 581-584.
[4] WANG Hao,Liang Binyong,MEI Bin. Progress in neoadjuvant therapy for hepatocellular carcinoma based on immune checkpoint inhibitors [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 332-335.
[5] YUAN Hao, TENG Jingyan, ZHANG Qiang. Research progress of immunotherapy in neoadjuvant therapy of esophageal cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(2): 210-212.
[6] CHEN Taoyu, WU Heshui. Current status and challenges of neoadjuvant therapy for pancreatic cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(7): 694-697.
[7] LONG Xinglin, XIE Songping, LIU Gaoli, ZHang Wenhan, HUANG Jie. Clinical efficacy of immunotherapy combined with chemotherapy sequential surgery for locally advanced esophageal cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(11): 1040-1043.
[8] SHEN Haoyuan, HU Chaohua. Top 10 Hotspots for Breast cancer Surgery [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(1): 97-100.
[9] . Research progress in neoadjuvant treatment of esophageal squamous cell carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(8): 784-787.
[10] TENG Jiping, YANG Zhiyin, HU Xiaohua.. The efficacy of gefitinib versus pemetrexed combined with nedaplatin in patients with stage ⅢA-N2 EGFR mutation-positive lung adenocarcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2020, 28(10): 938-942.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 735 .
[2] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 753 .
[3] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(10): 796 .
[4] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(11): 821 .
[5] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(11): 835 .
[6] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(11): 841 .
[7] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(11): 867 .
[8] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(11): 888 .
[9] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(12): 916 .
[10] . [J]. JOURNAL OF CLINICAL SURGERY, 2016, 24(12): 919 .